Beam Therapeutics (BEAM) Operating Income (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Operating Income data on file, last reported at -$107.2 million in Q1 2026.

• On a quarterly basis, Operating Income rose 10.12% year-over-year to -$107.2 million in Q1 2026; TTM through Mar 2026 was -$371.6 million, a 13.72% increase from a year earlier, with the FY2025 full-year figure at -$383.7 million, up 7.67% from the prior year.
• Operating Income for Q1 2026 stood at -$107.2 million, down from -$17.4 million in the prior quarter.
• Over the last five years, Operating Income for BEAM reached as high as $132.9 million in Q4 2023 and fell as low as -$126.8 million in Q3 2025.
• Historically, Operating Income has averaged -$83.6 million across 5 years, with a median of -$102.1 million in 2023.
• Across the five-year window, Operating Income surged 249.3% in 2023 and sank 175.3% in 2024, its largest moves.
• Year by year, Operating Income stood at -$89.0 million in 2022, then jumped by 249.3% to $132.9 million in 2023, then sank by 175.3% to -$100.0 million in 2024, then surged by 82.56% to -$17.4 million in 2025, then slumped by 514.59% to -$107.2 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$107.2 million in Q1 2026, -$17.4 million in Q4 2025, and -$126.8 million in Q3 2025.